哮喘合并酸反流患者临床采用埃索美拉唑联合莫沙必利治疗后抑酸和肺功能的疗效

doi:10.3877/cma.j.issn.2095-8765.2023.04.004

中华胃食管反流病电子杂志 ›› 2023, Vol. 10 ›› Issue (04) : 181 -186. doi: 10.3877/cma.j.issn.2095-8765.2023.04.004

论著

哮喘合并酸反流患者临床采用埃索美拉唑联合莫沙必利治疗后抑酸和肺功能的疗效

麦热哈巴·哈力克¹, 艾帕都拉·艾斯拉², 赵燕霞¹, 买买提·依斯热依力³, 魏雪梅¹^,^†(

), 克力木·阿不都热依木³

^1. 830001　乌鲁木齐，新疆维吾尔自治区人民医院呼吸与危重症医学中心
^2. 830001　乌鲁木齐，新疆维吾尔自治区人民医院耳鼻喉诊疗中心
^3. 830001　乌鲁木齐，新疆维吾尔自治区人民医院自治区普外微创研究所

收稿日期:2023-04-17 出版日期:2023-11-15
通信作者: 魏雪梅
基金资助:
新疆维吾尔自治区人民医院院内项目(20190420)

Analysis of the efficacy of acid suppression and pulmonary function after clinical treatment with esomeprazole combined with mosapride in patients with asthma combined with acid reflux

Halike Mairehaba·¹, Aisila Aipadula·², Yanxia Zhao¹, Yisireyili Maimaiti·³, Xuemei Wei¹^,^†(), Abudureyimu Kelimu·³

^1. Respiratory and Critical Care Medicine Center, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China
^2. Otolaryngology Diagnosis and Treatment Center, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China
^3. Resaerch Center for Minimally Invasive Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China

Received:2023-04-17 Published:2023-11-15
Corresponding author: Xuemei Wei

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

麦热哈巴·哈力克, 艾帕都拉·艾斯拉, 赵燕霞, 买买提·依斯热依力, 魏雪梅, 克力木·阿不都热依木. 哮喘合并酸反流患者临床采用埃索美拉唑联合莫沙必利治疗后抑酸和肺功能的疗效[J]. 中华胃食管反流病电子杂志, 2023, 10(04): 181-186.

Halike Mairehaba·, Aisila Aipadula·, Yanxia Zhao, Yisireyili Maimaiti·, Xuemei Wei, Abudureyimu Kelimu·. Analysis of the efficacy of acid suppression and pulmonary function after clinical treatment with esomeprazole combined with mosapride in patients with asthma combined with acid reflux[J]. Chinese Journal of Gastroesophageal Reflux Disease(Electronic Edition), 2023, 10(04): 181-186.

目的

探讨对于哮喘合并酸反流患者临床采用埃索美拉唑联合莫沙必利治疗后抑酸和肺功能的疗效。

方法

回顾性分析2020年6月至2021年12月在新疆维吾尔自治区人民医院呼吸与危重症医学中心住院的哮喘合并胃食管反流病（GERD）患者（51例），根据治疗方式的不同，进一步分为对照组（给予哮喘常规治疗）和研究组（对照组基础上给予埃索美拉唑联合枸橼酸莫沙必利）。收集患者临床一般信息，肺功能，GERD问卷（GERD-Q），哮喘控制测试（ACT）评分以及呼吸困难量表（mMRC）等相关辅助检查数据。2组患者均进行治疗8周，收集并分析2组患者治疗前后上述指标的改善情况。

结果

研究组改善酸反流症状（GERD-Q）评分、ACT评分以及mMRC评分指标的程度明显优于对照组，差异均有统计学意义（P<0.05）。2组患者治疗前及治疗后经肺功能检查分析发现，与对照组相比，研究组显著改善患者第一秒用力呼气容积/用力肺活量（FEV1/FVC）、氧分压及二氧化碳分压等指标，差异均有统计学意义（P<0.05）。对照组总有效率为64.00%，研究组为88.46%，差异有统计学意义（P<0.05）。

结论

采用埃索美拉唑联合枸橼酸莫沙必利治疗哮喘合并GERD效果优于常规治疗，值得进一步临床推广应用。

关键词: 胃食管反流病, 哮喘, 埃索美拉唑, 莫沙必利, 疗效

Objective

To investigate the efficacy of acid suppression and pulmonary function in patients with asthma combined with acid reflux after clinical treatment with esomeprazole in combination with mosapride.

Method

Patients with asthma combined with GERD (51 cases) hospitalized in the Respiratory and Critical Care Medicine Center of the People's Hospital of Xinjiang Uygur Autonomous Region from June 2020 to December 2021 were retrospectively analyzed and further divided into a control group (given conventional asthma treatment) and a study group (given esomeprazole combined with mosapride citrate on top of the control group) according to the treatment modality. General clinical information, lung function, GERDQ scale, asthma control test (ACT) score and Medical research association dyspnea scale (mMRC) were collected. Patients in both groups were treated for 8 weeks, and the improvement of the above indicators was collected and analyzed before and after treatment in both groups.

Result

The improvement of acid reflux symptoms (GERD-Q) score, ACT score, and mMRC score indicators in the research group was significantly better than that in the control group, and the differences were statistically significant (P<0.05). Two groups of patients underwent pulmonary function analysis before and after treatment, and it was found that compared with the control group, the study group significantly improved lung function indicators: first second forced expiratory volume/forced vital capacity (FEV1/FVC), oxygen partial pressure, and carbon dioxide partial pressure. The differences were statistically significant (P<0.05). The total effective rate of the control group was 64.00%, while that of the study group was 88.46%, with a statistically significant difference (P<0.05).

Conclusion

The use of esomeprazole combined with mosapride citrate in the treatment of asthma combined with GERD is more effective than conventional treatment and deserves further clinical application.

Key words: Gastroesophageal reflux disease, Asthma, Esomeprazole, Mosapride, Curative effect

表1 2组患者一般临床资料比较

组别	例数	性别(男性/女性)	年龄(岁, )	体质量指数(kg/m²)	病程(个月, )
对照组	25	16/9	55.80±6.87	25.34±3.47	8.60±1.29
研究组	26	15/11	57.07±7.19	26.48±3.32	8.11±2.25
χ²/t值		0.213	-0.648	-1.208	0.938
P值		0.645	0.520	0.233	0.353

表1 2组患者一般临床资料比较

组别	例数	性别(男性/女性)	年龄(岁, )	体质量指数(kg/m²)	病程(个月, )
对照组	25	16/9	55.80±6.87	25.34±3.47	8.60±1.29
研究组	26	15/11	57.07±7.19	26.48±3.32	8.11±2.25
χ²/t值		0.213	-0.648	-1.208	0.938
P值		0.645	0.520	0.233	0.353

表2 2组患者治疗前后酸反流和哮喘指标比较（分，

）

组别	例数	GERD-Q评分		ACT评分		mMRC评分
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	25	14.88±2.18	11.28±1.76^a	14.88±2.18	17.28±1.93^a	2.96±0.78	1.76±0.72^a
研究组	26	14.19±1.87	9.76±1.47^a	14.50±1.86	21.19±3.36^a	3.00±0.69	1.19±0.691^a
t值		1.207	3.316	0.670	-0.507	-0.193	2.860
P值		0.233	0.002	0.506	0.001	0.844	0.006

表2 2组患者治疗前后酸反流和哮喘指标比较（分，

）

组别	例数	GERD-Q评分		ACT评分		mMRC评分
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	25	14.88±2.18	11.28±1.76^a	14.88±2.18	17.28±1.93^a	2.96±0.78	1.76±0.72^a
研究组	26	14.19±1.87	9.76±1.47^a	14.50±1.86	21.19±3.36^a	3.00±0.69	1.19±0.691^a
t值		1.207	3.316	0.670	-0.507	-0.193	2.860
P值		0.233	0.002	0.506	0.001	0.844	0.006

表3 2组患者治疗前后肺功能指标比较（

）

组别	例数	FEV1/FVC（%）		PaO₂（mmHg）		PaCO₂（mmHg）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	25	65.48±5.92	76.12±6.13^a	63.32±7.78	83.62±4.47^a	50.76±4.51	39.48±3.73^a
研究组	26	67.42±6.69	79.53±4.30^a	65.53±8.23	86.11±3.71^a	49.23±5.14	36.92±3.27^a
t值		-1.095	-2.307	-0.985	-2.168	1.128	2.609
P值		0.279	0.025	0.330	0.035	0.265	0.012

表3 2组患者治疗前后肺功能指标比较（

）

组别	例数	FEV1/FVC（%）		PaO₂（mmHg）		PaCO₂（mmHg）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	25	65.48±5.92	76.12±6.13^a	63.32±7.78	83.62±4.47^a	50.76±4.51	39.48±3.73^a
研究组	26	67.42±6.69	79.53±4.30^a	65.53±8.23	86.11±3.71^a	49.23±5.14	36.92±3.27^a
t值		-1.095	-2.307	-0.985	-2.168	1.128	2.609
P值		0.279	0.025	0.330	0.035	0.265	0.012

表4 2组患者治疗效果比较 [例(%)]

组别	例数	痊愈	有效	无效	总有效率
对照组	25	7(28.00)	9(36.00)	9(36.00)	16(64.00)
研究组	26	13(50.00)	10(38.46)	3(11.54)^a	23(88.46)^a

表4 2组患者治疗效果比较 [例(%)]

组别	例数	痊愈	有效	无效	总有效率
对照组	25	7(28.00)	9(36.00)	9(36.00)	16(64.00)
研究组	26	13(50.00)	10(38.46)	3(11.54)^a	23(88.46)^a

1	Sundbom F, Janson C, Ljunggren M, et al. Asthma and asthma-related comorbidity: effects on nocturnal oxygen saturation[J]. J Clin Sleep Med, 2022, 18(11):2635-2641.
2	Martinucci I, Albano E, Marchi S, et al. Extra-esophageal presentation of gastroesophageal reflux disease: new understanding in a new era[J]. Minerva Gastroenterol Dietol, 2017, 63(3):221-234.
3	Kopsaftis Z, Yap HS, Tin KS, et al. Pharmacological and surgical interventions for the treatment of gastro-oesophageal reflux in adults and children with asthma[J]. Cochrane Database Syst Rev, 2021, 5(5):CD001496.
4	中华医学会消化病学分会. 2014年中国胃食管反流病专家共识意见[J]. 中华消化杂志,2014,34(10):649-661.
5	Flores L, Krause C, Pokala B, et al. Novel therapies for gastroesophageal reflux disease[J]. Curr Probl Surg, 2019, 56(12):100692.
6	Yu Y, Wen S, Wang S, et al. Reflux characteristics in patients with gastroesophageal reflux-related chronic cough complicated by laryngopharyngeal reflux[J].Ann Transl Med, 2019, 7(20):529.
7	Nazemiyeh M, Nouri-Vaskeh M, Somi MH, et al. Lung function parameters in patients with gastroesophageal reflux without respiratory symptoms: a case-control study[J].Gastroenterol Hepatol Bed Bench, 2019, 12(4):287-291.
8	杨凡,龚瑞雪. 埃索美拉唑联合枸橼酸莫沙必利对哮喘合并胃食管反流患者肺功能的影响[J]. 实用临床医药杂志,2016,20(13):155-156,162.
9	刘廷敏, 成永清. 消化内科胃食管反流病的临床治疗效果[J].中国城乡企业卫生, 2019, 34(4):17-21.
10	许玉双, 张翠萍, 杨鑫. 胃食管反流病相关肺损伤与肺癌发病研究进展[J]. 中国实用内科杂志, 2018, 38(10):961-963.
11	Lin S, Li H, Fang X. esophageal motor dysfunctions in gastroesophageal reflux disease and therapeutic perspectives[J]. J Neurogastroenterol Motil, 2019, 25(4):499-507.
12	王艳, 林琳, 姜柳琴. 胃食管反流病的食管动力异常研究进展[J]. 胃肠病学, 2019,24(5):311-314.
13	黎丽群, 谢胜, 陈明冰, 等. GerdQ量表对胃食管反流性疾病诊断价值的Meta分析[J].中国循证医学杂志, 2019, 19(8):62-65.
14	Hillman L, Yadlapati R, Thuluvath AJ, et al. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease[J]. Dis Esophagus, 2017, 30(9):1-15.
15	Qi Q, Wang R, Liu L, et al. Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophagealreflux disease: a systematic review and meta-analysis[J]. Int J Clin Pharmacol Ther, 2015, 53(10):803-810.
16	Komura M, Kanamori Y, Tanaka Y, et al. Mosapride for gastroesophageal reflux disease in neurologically impaired patients[J]. Pediatr Int, 2017, 59(3):347-351.
17	Fernando T, Goldman RD. Management of gastroesophageal reflux disease in pediatric patients with cerebral palsy[J]. Can Fam Physician, 2019, 65(11):796-798.
18	Zhuang ZH, Zou FM, Tang DP, et al. The 5-HT4 receptor agonist mosapride attenuates inflammation of reflux esophagitis [J]. Hepatogastroe nterology, 2014 ,61(129):115-119.
19	Liu Q, Feng CC, Wang EM, et al. Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: a systematic review [J]. World J Gastroenterol, 2013, 19(47):9111-9118.
20	佐拉木·买买提, 薛克栋. 胃食管反流病引起呼吸及循环系统急症的临床症状特点分析[J/OL]. 中华胃食管反流病电子杂志, 2017, 4(2):72-74.
21	崔亚, 姜礼双, 卜平.胃食管反流病发病机制的研究进展[J].中国实用医刊, 2018, 45(12):122-126,封3.
22	Piyasena IN, Jayasinghe JA. Mosapride (5HT4 agonist) in the treatment of blepharospasm[J]. Ceylon Med J, 2014, 59(1):26-27.
23	Kiljander TO. The role of proton pump inhibitors in the management of gastroesophageal reflux disease-related asthma and chronic cough[J]. Am J Med, 2003,115 Suppl 3A:65S-71S.
24	Kanemitsu Y, Kurokawa R, Takeda N, et al. Clinical impact of gastroesophageal reflux disease in patients with subacute/chronic cough[J]. Allergol Int, 2019, 68(4):478-485.
25	Kazyulin AN, Dicheva DT, Parcvania-Vinogradova EV, et al. Methodological features of the pH-metry in patients with a combination of gastroesophageal reflux disease and bronchial asthma[J]. Eksp Klin Gastroenterol, 2016(6):100-104.
26	Derbak M, Boldizhar O, Sirchak Y, et al. Combined course of bronchial asthma and gastroesophageal reflux disease: its clinical, functional peculiarities, and mechanisms of its correction[J]. Georgian Med News, 2017(272):69-74.

[1]	屈少华, 胡晔东, 赵修浩, 李文娜, 向鹏程, 肖子添, 马启明, 韩俊毅. 伴有无效食管动力的胃食管反流病用药和手术治疗的效果对比[J]. 中华普通外科学文献(电子版), 2024, 18(01): 23-28.
[2]	邢益民, 张天飞, 戴慧勇. 胃肠充盈超声造影检查在反酸、嗳气患者临床诊断中的应用[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 303-306.
[3]	鲁鑫, 杨琴, 许佳怡. 不同术式治疗恶性梗阻性黄疸疗效及对免疫功能的影响[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 180-183.
[4]	钟文涛, 吕远, 孙亮, 袁强, 聂玉辉, 东星, 陈光, 陈纲, 杜峻峰. 腹腔镜-胃镜联合手术与开腹手术处理胃间质瘤的临床疗效对比研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 164-166.
[5]	梁艳, 胡志伟, 刘健男, 宋庆, 陈冬, 田书瑞, 李冉, 毛建新. 高分辨率食管测压在胃食管反流病食管运动功能评价中的应用[J]. 中华疝和腹壁外科杂志(电子版), 2024, 18(01): 89-92.
[6]	暴静, 吴霞, 田雅萍, 尹钢. 维生素D₃联合孟鲁司特钠治疗支气管哮喘对血清VEGF、TGF-β1及肺功能的影响[J]. 中华肺部疾病杂志(电子版), 2024, 17(01): 63-67.
[7]	周璐, 钱桂亮, 黄建, 辛永利. 不同剂量亚胺培南西司他丁钠治疗重症肺炎的疗效分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(01): 73-77.
[8]	张鑫, 陈美池, 褚雪镭, 高音, 朱世杰. 劳拉替尼治疗晚期非小细胞肺癌的疗效分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(01): 83-86.
[9]	陈华萍, 陈晓龙, 胡明冬. 难治性哮喘的发病机制及诊治进展[J]. 中华肺部疾病杂志(电子版), 2024, 17(01): 144-147.
[10]	朱斯悦, 张晓莹, 严玉茹, 陈绯. 介入支气管镜在肺部疾病诊断和治疗中的应用[J]. 中华肺部疾病杂志(电子版), 2024, 17(01): 148-151.
[11]	李浩南, 张煜彭, 付焱, 冯继伟, 刘凯, 张文凯. 缝隙连接蛋白43在肺部疾病中的研究进展[J]. 中华重症医学电子杂志, 2024, 10(01): 60-65.
[12]	刘萍, 刘占举, 张萃. 英夫利西单抗治疗克罗恩病的临床疗效及影响因素[J]. 中华消化病与影像杂志(电子版), 2024, 14(01): 28-34.
[13]	谢鸿, 李娜, 李尚日, 谢涛. 肠道菌群特征对结肠癌化学治疗疗效的影响[J]. 中华消化病与影像杂志(电子版), 2024, 14(01): 53-56.
[14]	葛雪梅. SOX与mFOLFOX6化疗方案对晚期胃癌的疗效与安全性[J]. 中华消化病与影像杂志(电子版), 2024, 14(01): 67-71.
[15]	庞宁东, 蒋贻洲, 姜华, 牛传强, 李海波, 刘浪, 刘珍银, 张靖. 经皮腔内血管成形术治疗儿童肾动脉狭窄的疗效及相关因素分析[J]. 中华介入放射学电子杂志, 2024, 12(01): 22-26.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Analysis of the efficacy of acid suppression and pulmonary function after clinical treatment with esomeprazole combined with mosapride in patients with asthma combined with acid reflux

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Analysis of the efficacy of acid suppression and pulmonary function after clinical treatment with esomeprazole combined with mosapride in patients with asthma combined with acid reflux